RoslinCT Rating A · Worker

RoslinCT is a contract development and manufacturing organisation (CDMO) that specialises in cell and gene therapies. The company supports therapy developers by translating complex biological processes into clinical and commercial-grade programs. It works across immunotherapies, gene-edited therapies, and stem cell platforms, with a particular focus on clinical-grade human pluripotent stem cells.

The organisation operates manufacturing suites to support both autologous and allogeneic manufacturing. Its services include process and analytical development, clinical and commercial manufacturing, cell banking, and regulatory compliance. In collaboration with Vertex Pharmaceuticals, the company helped develop the first CRISPR-edited cell therapy product for sickle cell disease and beta thalassemia.